*Please note that this translation is to be used solely as reference.
In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.
Supplementary Information of Consolidated
Financial Results
for the Nine Months ended December 31, 2024
Feb 14, 2025
Linical Co., Ltd.
TSE Standard 2183
Consolidated Financial Results
Units:
millions of yen, %
Net Sales
Cost of Sales
SG&A
Expenses
Operating
Profit
Ordinary Profit
Net Profit
Results for the Nine | Results for the Nine Months Ended | |||
Months Ended | ||||
December 31, 2024 | ||||
December 31, 2023 | ||||
Amount | Sales Ratio | Amount | Sales Ratio | Year-on- |
Year | ||||
9,248 | 100.0 | 7,955 | 100.0 | △14.0 |
6,276 | 67.9 | 6,097 | 76.6 | △2.9 |
2,330 | 25.2 | 2,189 | 27.5 | △6.1 |
641 | 6.9 | △332 | △4.2 | ー |
632 | 6.8 | △261 | △3.3 | ー |
253 | 2.7 | △316 | △4.0 | ー |
Net sales: Consolidated net sales decreased year-on-year, as sales in the United States increased, but sales in other regions decreased.
Operating profit:
Profit on a consolidated basis also decreased year-on-year, as profit in the United States increased, but other regions posted an operating loss.
2
Financial Results by Region
Results for the Nine Months | Results for the Nine Months Ended December 31, 2024 | |||||||||
Unit: | Ended December 31, 2023 | |||||||||
Millions of yen | Net Sales | Operating | Ordinary | Net Sales | Rate of | Operating | Rate of | Ordinary | Rate of | |
** | Profit | Profit | Change % | Profit | Change % | Profit | Change % | |||
Japan | 3,936 | 398 | 458 | 2,794 | △29.0 | △374 | － | △346 | － | |
United | 3,325 | 516 | 534 | 3,603 | 8.3 | 543 | 5.3 | 575 | 7.8 | |
States | ||||||||||
Europe | 2,424 | △53 | △117 | 2,334 | △3.7 | △63 | － | △101 | － | |
Korea | 703 | 72 | 63 | 544 | △22.6 | △91 | － | △37 | － | |
Taiwan | 72 | △22 | △24 | 58 | △19.7 | △37 | － | △36 | － | |
China | 231 | △48 | △52 | 155 | △32.7 | 1 | － | △1 | － | |
ConsolidationAdjustments* | △1,444 | △221 | △228 | △1,535 | △309 | △313 | ||||
Total | 9,248 | 641 | 632 | 7,955 | △14.0 | △332 | － | △261 | － | |
3 | ||||||||||
* Amortization of goodwill is included in consolidation adjustments. ** Net sales have calculated before deducting internal transactions. | ||||||||||
Hard Backlog by Region
* Hard backlog:
The balance of the amount for orders for contract business already concluded.
This is an indicator that shows the amount of sales to be generated over the next one to five years and serves as the basis for the group's future results forecasts.
(Millions of yen) | 12,665 | ||||||
12,188 | 11,302 | 12,427 | |||||
1,315 | |||||||
1,434 | 10,965 | 1,341 | |||||
1,317 | |||||||
10,000 | 3,655 | 3,383 | 1,200 | 3,518 | |||
3,211 | 2,702 | Asia | |||||
5,000 | 3,221 | 4,194 | 3,188 | 3,114 | 3,531 | EU | |
US | |||||||
Japan
3,877 | 3,772 | 3,584 | 3,947 | 4,036 | |
0 | |||||
2024/3 | 2024/6 | 2024/9 | 2024/12 | 2025/2/14 |
- Order (hard) backlog as of Feb 14, 2025, was worth 12.4 billion yen, up 2.0% from the end of
March 2024 | 4 |
Hard Backlog by Region
- Japan/Asia:
- Japan continues to face difficult market conditions, but the order backlog as of December 31, 2024 and Feb 14, 2025 exceeded that at the end of March 2024
- In South Korea, new orders did not progress due to the continued impact of the medical strike. Currently, the company has succeeded in receiving many orders from overseas clients through collaboration with its group companies in Japan and Asia.
- United States:
- The order backlog increased compared with the end of March 2024 due to the winning of new projects and changes in contracts for existing projects to increase person-hours
- Sales activities to expand orders are accelerated due to high inquiries from biotechnology companies.
- Europe:
- The synergy effect of management integration in Europe and the United States has led to new orders.
• Hiring sales personnel to increase new orders in Europe | 5 |
Full-Year Forecast
FY ended March | FY ending March 2025 | FY ending March 2025 | ||||||
Unit: | 2024 | Previous Forecasts | Latest Forecasts | |||||
Millions of yen | Amount | Sales Ratio | Amount | Sales Ratio | Rate of | Amount | Sales Ratio | Rate of |
Change | Change | |||||||
Net Sales | 12,307 | 100.0 | 11,468 | 100.0 | △6.8 | 10,430 | 100.0 | △9.1 |
Operating | 725 | 5.9 | 250 | 2.2 | △65.6 | △650 | △5.9 | － |
Profit | ||||||||
Ordinary | 790 | 6.4 | 258 | 2.2 | △67.3 | △550 | △5.0 | － |
Profit | ||||||||
Net Profit | 338 | 2.7 | 150 | 1.3 | △55.7 | △570 | △5.2 | － |
The full-year forecast was revised on February 14, 2025.
6
Cautionary Notes
Those plans, forecasts, strategies, etc., stated in this document that are not historical facts are forecasts concerning future results. These are forecasts that have been determined by the company based on information currently available so please do not place undue reliance on them.
Please understand that the company will bear no responsibility whatsoever for any damage, etc., resulting from errors in the information stated in this document. In addition, this document is not aimed at soliciting investment.
Users are asked to make investment decisions at their own judgment.
7